Glioblastom

Glioblastome gehören zu den häufigsten primären Tumoren im Zentralnervensystem (ZNS). Die Diagnosestellung erfolgt anhand histomorphologischer und molekularer Kriterien, die jüngst durch die Weltgesundheitsorganisation (WHO) neu definiert wurden. Die leitliniengerechte Therapie besteht aus neurochirurgischer Intervention (Biopsie oder Resektion) und anschließend im Wesentlichen aus einer Kombination der Modalitäten Radiotherapie, Chemotherapie (Temozolomid, ggf. kombiniert mit Lomustin) und ggf. Tumortherapiefelder. Klinische Therapiestudien sind integraler Bestandteil einer modernen neuroonkologischen Versorgung. In den aktuellen Phase-I/II-Studien kommen innovative Biomarker-basierte Therapiekonzepte zum Einsatz, teils mit molekular zielgerichteten Substanzen, teils mit personalisierter Immuntherapie.

Schlüsselwörter

Neuroonkologie - Glioblastom - Therapie

Publication History

Article published online:
06 May 2022

• Literatur

• 1 Louis DN, Perry A, Wesseling P. et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021; 23 (08) 1231-1251 DOI: 10.1093/neuonc/noab106. (PMID: 34185076)
• 2 Ostrom QT, Cioffi G, Waite K. et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014–2018. Neuro Oncol 2021; 23 (Suppl. 12) iii1-iii105 DOI: 10.1093/neuonc/noab200. (PMID: 34608945)
• 3 Sadetzki S, Chetrit A, Freedman L. et al. Long-term follow-up for brain tumor development after childhood exposure to ionizing radiation for tinea capitis. Radiat Res 2005; 163 (04) 424-432 DOI: 10.1667/rr3329. (PMID: 15799699)
• 4 Wick W. Gliome, S2k-Leitlinie, 2021, in: Deutsche Gesellschaft für Neurologie (Hrsg.), Leitlinien für Diagnostik und Therapie in der Neurologie. Accessed December 25, 2021 at: www.dgn.org/leitlinien
• 5 Molinaro AM, Hervey-Jumper S, Morshed RA. et al. Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma. JAMA Oncol 2020; 6 (04) 495-503 DOI: 10.1001/jamaoncol.2019.6143. (PMID: 32027343)
• 6 Weller M, van den Bent M, Preusser M. et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 2021; 18 (03) 170-186 DOI: 10.1038/s41571-020-00447-z. (PMID: 33293629)
• 7 Armstrong TS, Cohen MZ, Eriksen LR. et al. Symptom clusters in oncology patients and implications for symptom research in people with primary brain tumors. J Nurs Scholarsh 2004; 36 (03) 197-206 DOI: 10.1111/j.1547-5069.2004.04038.x. (PMID: 15495487)
• 8 Coomans MB, Dirven L, Aaronson NK. et al. Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status?. Neuro Oncol 2019; 21 (11) 1447-1457 DOI: 10.1093/neuonc/noz118. (PMID: 31682733)
• 9 Nayak L, DeAngelis LM, Brandes AA. et al. The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. Neuro Oncol 2017; 19 (05) 625-635 DOI: 10.1093/neuonc/nox029. (PMID: 28453751)
• 10 Wen PY, Macdonald DR, Reardon DA. et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010; 28 (11) 1963-1972 DOI: 10.1200/JCO.2009.26.3541. (PMID: 20231676)
• 11 Okada H, Weller M, Huang R. et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol 2015; 16 (15) e534-e542 DOI: 10.1016/S1470-2045(15)00088-1. (PMID: 26545842)
• 12 Weller M, Stupp R, Reifenberger G. et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine?. Nat Rev Neurol 2010; 6 (01) 39-51 DOI: 10.1038/nrneurol.2009.197. (PMID: 19997073)
• 13 Herrlinger U, Tzaridis T, Mack F. et al. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet 2019; 393: 678-688 DOI: 10.1016/S0140-6736(18)31791-4. (PMID: 30782343)
• 14 Perry JR, Laperriere N, OʼCallaghan CJ. et al. Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. N Engl J Med 2017; 376 (11) 1027-1037 DOI: 10.1056/NEJMoa1611977. (PMID: 28296618)
• 15 Stupp R, Taillibert S, Kanner A. et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA 2017; 318 (23) 2306-2316 DOI: 10.1001/jama.2017.18718. (PMID: 29260225)
• 16 Balana C, Vaz MA, Manuel Sepulveda J. et al. A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14–01). Neuro Oncol 2020; 22 (12) 1851-1861 DOI: 10.1093/neuonc/noaa107. (PMID: 32328662)
• 17 Wick W, Platten M, Meisner C. et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012; 13 (07) 707-715 DOI: 10.1016/S1470-2045(12)70164-X. (PMID: 22578793)
• 18 Le Rhun E, Preusser M, Roth P. et al. Molecular targeted therapy of glioblastoma. Cancer Treat Rev 2019; 80: 101896 DOI: 10.1016/j.ctrv.2019.101896. (PMID: 31541850)
• 19 Di Stefano AL, Fucci A, Frattini V. et al. Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma. Clin Cancer Res 2015; 21 (14) 3307-3317 DOI: 10.1158/1078-0432.CCR-14-2199. (PMID: 25609060)
• 20 Fusco MJ, Pina Y, Macaulay RJ. et al. Durable Progression-Free Survival With the Use of BRAF and MEK Inhibitors in Four Cases With BRAF V600E-Mutated Gliomas. Cancer Control 2021; 28 DOI: 10.1177/10732748211040013. (PMID: 34620004)
• 21 Hong DS, DuBois SG, Kummar S. et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol 2020; 21 (04) 531-540 DOI: 10.1016/S1470-2045(19)30856-3. (PMID: 32105622)
• 22 Ringel F, Pape H, Sabel M. et al. Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection. Neuro Oncol 2016; 18 (01) 96-104 DOI: 10.1093/neuonc/nov145. (PMID: 26243790)
• 23 Suchorska B, Weller M, Tabatabai G. et al. Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial. Neuro Oncol 2016; 18 (04) 549-556 DOI: 10.1093/neuonc/nov326. (PMID: 26823503)
• 24 Levin VA, Bidaut L, Hou P. et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 2011; 79 (05) 1487-1495 DOI: 10.1016/j.ijrobp.2009.12.061. (PMID: 20399573)
• 25 Weller M, Le Rhun E. How did lomustine become standard of care in recurrent glioblastoma?. Cancer Treat Rev 2020; 87: 102029 DOI: 10.1016/j.ctrv.2020.102029. (PMID: 32408220)
• 26 Lombardi G, De Salvo GL, Brandes AA. et al. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol 2019; 20 (01) 110-119 DOI: 10.1016/S1470-2045(18)30675-2. (PMID: 30522967)
• 27 Di Tacchio M, Macas J, Weissenberger J. et al. Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF. Cancer Immunol Res 2019; 7 (12) 1910-1927 DOI: 10.1158/2326-6066.CIR-18-0865. (PMID: 31597643)
• 28 Jackson CM, Choi J, Lim M. Mechanisms of immunotherapy resistance: lessons from glioblastoma. Nat Immunol 2019; 20 (09) 1100-1109 DOI: 10.1038/s41590-019-0433-y. (PMID: 31358997)
• 29 Persico P, Lorenzi E, Dipasquale A. et al. Checkpoint Inhibitors as High-Grade Gliomas Treatment: State of the Art and Future Perspectives. J Clin Med 2021; 10 (07) DOI: 10.3390/jcm10071367. (PMID: 33810532)
• 30 Cloughesy TF, Mochizuki AY, Orpilla JR. et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med 2019; 25 (03) 477-486 DOI: 10.1038/s41591-018-0337-7. (PMID: 30742122)
• 31 Schalper KA, Rodriguez-Ruiz ME, Diez-Valle R. et al. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Nat Med 2019; 25 (03) 470-476 DOI: 10.1038/s41591-018-0339-5. (PMID: 30742120)
• 32 Chinot OL, Wick W, Mason W. et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014; 370 (08) 709-722 DOI: 10.1093/neuonc/now091. (PMID: 27515827)
• 33 Gilbert MR, Dignam JJ, Armstrong TS. et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014; 370 (08) 699-708 DOI: 10.1056/NEJMoa1308573. (PMID: 24552317)
• 34 Wick W, Gorlia T, Bendszus M. et al. Lomustine and Bevacizumab in Progressive Glioblastoma. N Engl J Med 2017; 377 (20) 1954-63 DOI: 10.1056/NEJMoa1707358. (PMID: 29141164)
• 35 Pace A, Dirven L, Koekkoek JAF. et al. European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma. Lancet Oncol 2017; 18 (06) e330-e340 DOI: 10.1016/S1470-2045(17)30345-5. (PMID: 28593859)
• 36 Pitter KL, Tamagno I, Alikhanyan K. et al. Corticosteroids compromise survival in glioblastoma. Brain 2016; 139 (05) 1458-1471 DOI: 10.1093/brain/aww046. (PMID: 27020328)
• 37 Roth P, Wick W, Weller M. Steroids in neurooncology: actions, indications, side-effects. Curr Opin Neurol 2010; 23 (06) 597-602 DOI: 10.1097/WCO.0b013e32833e5a5d. (PMID: 20962642)
• 38 Vecht CJ, Hovestadt A, Verbiest HB. et al. Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. Neurology 1994; 44 (04) 675-680 DOI: 10.1212/wnl.44.4.675. (PMID: 8164824)
• 39 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK A. Psychoonkologische Diagnostik, Beratung und Behandlung von erwachsenen Krebspatienten. In: Langversion 1.0, AWMF-Registernummer: 032/051OL.. http://leitlinienprogramm-onkologie.de/Leitlinien.7.0.html editor: 2014
• 40 Moss AH, Lunney JR, Culp S. et al. Prognostic significance of the “surprise” question in cancer patients. J Palliat Med 2010; 13 (07) 837-840 DOI: 10.1089/jpm.2010.0018. (PMID: 20636154)
• 41 Fritz L, Zwinkels H, Koekkoek JAF. et al. Advance care planning in glioblastoma patients: development of a disease-specific ACP program. Support Care Cancer 2020; 28 (03) 1315-1324 DOI: 10.1007/s00520-019-04916-9. (PMID: 31243585)
• 42 Ciciola P, Cascetta P, Bianco C. et al. Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents. J Clin Med 2020; 9 (03) 675 DOI: 10.3390/jcm9030675. (PMID: 32138216)